Human medicinal products · Our core expertise
Marketing Authorisation of Human Medicinal Products
We provide dossier preparation and follow-up services in line with TİTCK requirements for human medicinal products, from the marketing authorisation application through to all post-authorisation activities.
Scope of service
From application to post-authorisation, one team
Application dossier
- Review of marketing authorisation application dossiers against TİTCK requirements
- Preparation and/or translation of marketing authorisation dossiers in CTD/eCTD format
- Preparation of Module 2.4 and 2.5 overviews
- Preparation of analytical documentation
- Preparation and revision of the SmPC and PIL
- Preparation, conduct and reporting of PIL readability (user) testing
Process management
- Follow-up of the preliminary review and authorisation procedures until the marketing authorisation is granted
- Technical support in completing information and documents requested by the authorisation committees
- Handling and follow-up of correspondence with the Ministry of Health
- Liaison with licensors and active substance manufacturers; obtaining CEP, DMF and GMP documents
- Preparation of documentation for on-site GMP and risk-based inspections
Post-authorisation and import
- Preparation of variation and renewal applications
- Preparation of marketing authorisation transfer applications
- Customs exemption, control certificate and import notification applications
Frequently asked questions
Common questions on MA applications
Answers are based on the TİTCK Medicines Licensing Department’s Frequently Asked Questions document (16.02.2024) and the Guideline on Packaging Information and Patient Leaflets for Human Medicinal Products (İRD-KLVZ-07, revision 18, 11.08.2026), and are for general information only. Current legislation and Agency announcements prevail.
Are marketing authorisation applications submitted on paper?
No. Under Article 6 of the Regulation on the Licensing of Medicinal Products for Human Use, applications are accepted only electronically (e-CTD), except where the Agency decides otherwise or in cases of force majeure. All correspondence during the process is also electronic. Module 1 documents may be submitted with an e-signature instead of a wet signature. We prepare your dossier in e-CTD format, upload it and follow up all correspondence with TİTCK on your behalf.
Which parts of the dossier must be in Turkish?
As a rule, documents are submitted in Turkish. All Module 1 documents require a sworn Turkish translation. The clinical and non-clinical summaries in Module 2, and the purpose, interpretation and evaluation sections of Module 3, must also be in Turkish. Some Module 3 parts, such as validation studies and stability tables, and Modules 4 and 5 may be submitted in English. Our own medical translation team translates authorisation dossiers.
Do GMP and manufacturing authorisation documents from abroad need an apostille?
Official documents issued abroad must, as a rule, carry an apostille or consular legalisation. However, no apostille is required for current manufacturing authorisations and GMP certificates published on the official EUDRA GMP and FDA websites. GMP certificates without an expiry date are accepted as valid for 3 years from the inspection date.
Must the readability test be completed at the time of application?
No. Pre-review can be completed once the test protocol and a commitment to complete the test are submitted in Module 1.3.4. However, the licensing process cannot be concluded until the test results have been submitted. Products that have an SmPC but no patient information leaflet are exempt from the test. We also prepare readability tests and bridging reports as part of our PIL readability testing service.
In what order are applications taken into evaluation?
Applications that pass pre-review are placed on the scheduling list. Under the 4th revision of the Scheduling Guideline (İRD-KLVZ-22) of 4 June 2026, the list is ordered first by product group priority and, within each group, by the date of the complete application. The priority order is: first biosimilars, first pharmaceutical equivalents, products containing active substances on the Foreign Active Substance List, innovative products, blood products, other biological products, allergen products, hybrid products, reference medicinal products, essential medicines and other products. Processes are started only in February, May, August and November, and only for the number of applications set for each group (e.g. 3 first biosimilars and 5 first pharmaceutical equivalents; all innovative and reference products). Products that have waited through two scheduling rounds are started in the third. Applications submitted before 1.1.2024 are placed at the top, ordered by submission date alone. Products prioritised by the Priority Evaluation Board are started without being placed on the scheduling list.
Can a generic application be filed before the reference product’s data exclusivity expires?
Yes. If the reference product is authorised in Türkiye, an application for an equivalent (generic) medicinal product may be filed even if the data exclusivity period has not yet expired. This does not prevent the application from passing pre-review.
Is there a faster route for products approved in other countries?
Under the reliance provisions of Article 37/A of the Regulation, an accelerated, WHO-collaborative licensing procedure can be used for products approved by reference regulatory authorities. A pre-application is first filed with the Pre-Review (CTD) Unit; if it is found suitable, the marketing authorisation application is submitted under the reliance route. We can assess together whether your product qualifies and which documents are required.
Can scientific advice be obtained from TİTCK, and is it binding?
Yes. Applications can be made under the Scientific Advice Guideline for Human Medicinal Products, including for products that are already authorised. Separate applications are required for quality, clinical, BA/BE and biosimilar topics. Advice is for guidance only and is not legally binding on either the Agency or the applicant for any future application.
How are changes to packaging information or the PIL made?
Changes to packaging information and the PIL that fall outside the SmPC must be submitted to TİTCK before they are implemented. If the change is part of a variation, only the area affected by that variation is changed in the latest approved text, and the approval covers that area only. After approval, the ePIL and any audio PIL must be updated within 30 days, and multimedia QR code content must also be brought in line with the approved PIL.
When is a driving warning triangle required on the pack?
The outer packaging of products whose PIL states that they may impair the ability to drive or use machines must carry a warning triangle. Triangles have three levels according to the active substance: yellow (low risk), orange (case-by-case assessment; a healthcare professional should be consulted) and red (do not drive during treatment). The level follows the Driving Warning Triangles ATC Code Level List published on the TİTCK website; for active substances not on the list that still affect driving, a pictogram without a risk level is used.
Which products need a tamper-evident feature?
The outer packaging of red- and green-prescription medicines and of medicines under monitoring dispensed on normal prescription must carry a feature showing whether the pack has been opened: a security seal, a transparent overwrap that does not obscure labelling, an adhesive side flap or a carton with a perforated (tear-off) opening. The obligation applies from 01.07.2025 for red- and green-prescription medicines and from 01.07.2026 for medicines under monitoring.
How should the product name and pharmaceutical form appear on the pack?
With revision 18 (11.08.2026), the provisions on product name, strength, pharmaceutical form and route of administration were aligned with the Guideline on the Naming of Human Medicinal Products. If a product contains up to three active substances that are not part of its name, their common names are stated after the full name (below the name/strength/pharmaceutical form line); with more than three, they may appear elsewhere on the outer packaging. Pharmaceutical forms follow the Pharmaceutical Dosage Forms List of the Naming Guideline; short terms may only be used where the standard term does not fit in 7-point type (e.g. on blisters and small packs). The main therapeutic group is not stated on the pack.
